A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis

Psoriatic Arthritis Clinical Trial

Official title:

A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00963313
• Other study ID #: SUE-ADA-2009-01
• Status: Completed
• Phase: N/A
• First received: August 20, 2009
• Last updated: September 22, 2014
• Start date: March 2010
• Est. completion date: June 2014

Study information

• Verified date: September 2014
• Source: Instituto de Investigacion Biomedica de A Coruna
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Ethics Committee
• Study type: Observational

Clinical Trial Summary

Based on published data and according to the approved product label for ankylosing spondylitis and psoriatic arthritis, it can be expected that adalimumab 40 mg every 14 days should be effective in psoriatic arthritic patients with axial involvement.

Description:

A recent review from GRAPPA group evaluates therapies for PsA including peripheral and axPsA. Analysing particularly the results with present biologic therapies it has been proven that outcome data at 24 weeks show excellent results in the treatment of peripheral forms of PsA with either of the three biologics disposable in the market, that is to say infliximab, etanercept and adalimumab.

However when it comes to analyse data on PsA patients with axPsA there are not results at all. The design of clinical trials did not evaluate axial outcomes and therefore there is not a possibility of knowing whether these therapies are useful in axPsA.

This is an open label multicenter study designed to evaluate the effectivity of adalimumab 40 mg every 2 weeks during 24 weeks in patients with active axial PsA despite receiving Methotrexate, Sulfasalazine, Leflunomide or Cyclosporine, plus NSAIDs and no more than 10 mg of corticosteroids.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 29
• Est. completion date: June 2014
• Est. primary completion date: June 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Males and females aged between 18 and 70 years.

• A negative pregnancy test for women of childbearing potential during the screening period.

• Subject must be evaluated for active or latent TB (tuberculosis) infection by using a PPD skin test (Mantoux test), Booster test, chest x-ray and detailed review of subjetc´s medical history.

• Subjects to whom the doctor has decided to prescribe adalimumab, because of fulfilling the requirements for this treatment.

• Diagnosed with PsA according to CASPAR criteria.

• Axial disease according to radiological criteria (at least unilateral sacroilitis grade II) and spinal inflammatory symptoms.

• Disease duration of no less than 24 weeks

• Patients with peripheral involvement (mixed forms of APs) must have been taking MTX for at least 12 weeks before screening and at stable doses of 10 to 25 mg/week for 8 weeks before screening, or salazopyrine up to 3 mg/daily, or cyclosporin 2mg/kg or leflunomide 20 mg daily in the same conditions as MTX.

• Patient's doses of NSAIDs and oral corticosteroids (= 10 mg/day of prednisone or equivalent) should have been kept stable for 4 weeks before screening.

Exclusion Criteria:

• Contraindications for treatment with anti-TNF.

• Prior treatment with other TNF inhibitors or other investigational drugs during the last 30 days (etanercept 4 weeks, infliximab 8 weeks).

• Uncontrolled diabetes.

• Uncontrolled high blood pressure.

• Unstable ischemic heart disease.

• Congestive heart failure.

• Severe pulmonary disease.

• Chronic leg ulcer.

• History of cancer or malignant lymphoproliferative disease.

• Positive serology for Hepatitis B indicating active infection or positive serology for Hepatitis C.

• History of positive HIV status.

• Persistent, recurrent or severe infections requiring hospitalization or treatment with oral antibiotics within 14 days prior to enrollment.

• Previous diagnosis or signs highly indicative of central nervous system demyelinating diseases.

• Active tuberculosis, histoplasmosis or listeriosis.

• History or presence of confirmed blood dyscrasia.

• Female subjects who are pregnant or breast-feeding.

• History of clinically significant drug or alcohol abuse in the last year.

• Treatment with MTX, salazopyrine, ciclosporin or leflunomide initiated within the last 4 weeks before the screening. Treatment with corticosteroids (>10mg/day or equivalent or modified dose within the previous 4 weeks before screening). And patients where an intraarticular corticoid infiltration has been practised within the last 4 weeks before the screening will be excluded from the study.

• Treatment with more than one NSAID within the last 4 weeks before the screening.

• Patients treated with any DMARD different from MTX, cyclosporine, leflunomide and sulfasalazine.

• Dosage of concomitant MTX, cyclosporine, leflunomide and sulfasalazine must be stable during the study, otherwise it should be properly justified and recorded in the case report form.

• Patients treated with any analgesic different from acetominophen, NSAIDs, oxycodone, codeine, propoxyphene, tramadol, hydrocodone or combinations of these products or equivalents. The use of potent opioids is not permitted.

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Psoriatic
• Psoriatic Arthritis

Intervention

Drug:
• Adalimumab (HUMIRA®)
Prefilled syringes containing 40 mg Adalimumab in 0.8 ml injection solution. Study drug will be subcutaneously self-administered every 2 weeks during 24 weeks.

Locations

Country	Name	City	State
Spain	Complejo Hospitalario Universitario A Coruna	A Coruna
Spain	Hospital del Mar	Barcelona
Spain	Hospital Vall d´Hebron	Barcelona
Spain	Hospital Basurto	Bilbao
Spain	Hospital San Pedro de Alcantara	Caceres
Spain	Hospital Universitario Reina Sofia	Cordoba
Spain	Hospital de Elche	Elche	Alicante
Spain	Hospital Arquitecto Marcide-Novoa Santos	Ferrol	A Coruna
Spain	Hospital General de Jerez	Jerez de la Frontera	Cadiz
Spain	Hospital Bellvitge	L´Hospitalet de Llobregat	Barcelona
Spain	Hospital Doctor Negrin	Las Palmas	Gran Canaria
Spain	Hospital Insular de Las Palmas	Las Palmas	Gran Canaria
Spain	Hospital Orense	Orense
Spain	Hospital Central de Asturias	Oviedo	Asturias
Spain	Hospital Monte Naranco	Oviedo	Asturias
Spain	Hospital Pontevedra	Pontevedra
Spain	Hospital Parc Tauli	Sabadell	Barcelona
Spain	Hospital de Salamanca	Salamanca
Spain	Hospital Donostia	San Sebastian
Spain	Hospital Virgen de la Macarena	Sevilla
Spain	Hospital Meixoeiro	Vigo	Pontevedra
Spain	Hospital Comarcal Villajoyosa	Villajoyosa	Alicante

Sponsors (1)

Lead Sponsor	Collaborator
Dr. FRANCISCO J. BLANCO-GARCIA

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	BASDAI score (Bath Ankylosing Spondylitis Disease Activity Index).	Proportion of patients that reach a BASDAI 50% at week 12, BASDAI 50% means an improvement from baseline of 50% or an improvement of two units on a 10 unit scale.	12 WEEKS	No
Primary	Number of participants with new adverse events.		24 WEEKS	Yes
Secondary	ASAS 40 score.		24 WEEKS	No
Secondary	ASAS 50 and ASAS 70 score, 5/6.		12 WEEKS	No
Secondary	Evaluation of enthesitis.		24 WEEKS	No
Secondary	Peripheral articulation measured with DAS 28.		24 WEEKS	No
Secondary	Evaluation of extraarticular manifestations.		24 WEEKS	No
Secondary	Measure of laboratory parameters.	Hematology, biochemistry, CRP, ESR, HLA-B27 and rheumatoid factor.	24 WEEKS	No
Secondary	Evaluation of quality of life.	SF36	24 WEEKS	No
Secondary	Measure of PASI (Psoriasis Area and Severity Index).		24 WEEKS	No
Secondary	Measure of Modified NAPSI (Modified Nail Psoriasis Severity Index).		24 WEEKS	No
Secondary	Measure of BASFI (Bath Ankylosing Spondylitis Functioning Index).		24 WEEKS	No
Secondary	Evaluation of health.	HAQ (Health Assessment Questionarie).	24 WEEKS	No
Secondary	Evaluation of dactylitis.		24 WEEKS	No
Secondary	Measure of inflammatory biomarkers (IL6 and MMP3).		24 WEEKS	No